Moreover, galunisertib 35 triggers the pyroptotic pathway in glioblastoma, pancreatic cancer, and hepatocellular carcinoma through caspase-1/GSDMD activation [137, 138]. This evidence concerns the gene GSDMD and hepatocellular carcinoma.